Bioventus (NASDAQ:BVS) Trading Down 6.8% – What’s Next?

Bioventus Inc. (NASDAQ:BVS) dropped 6.8% during trading on Wednesday . The company traded as low as $8.60 and last traded at $8.4050. Approximately 334,402 shares were traded during trading, a decline of 17% from the average daily volume of 403,737 shares. The stock had previously closed at $9.02.

Analyst Upgrades and Downgrades

BVS has been the topic of a number of research reports. Barrington Research reissued an “outperform” rating and set a $14.00 target price on shares of Bioventus in a research report on Friday, May 22nd. Craig Hallum raised their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, CJS Securities assumed coverage on shares of Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Stock Performance

The business’s 50-day moving average price is $9.68 and its 200-day moving average price is $8.53. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The stock has a market cap of $719.45 million, a PE ratio of 21.06, a P/E/G ratio of 1.15 and a beta of 0.72.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The firm had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities research analysts expect that Bioventus Inc. will post 0.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares in the company, valued at $395,523.63. This trade represents a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.00% of the stock is owned by company insiders.

Institutional Trading of Bioventus

A number of institutional investors have recently bought and sold shares of BVS. Nantahala Capital Management LLC boosted its stake in Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock worth $34,959,000 after purchasing an additional 1,155,192 shares in the last quarter. Hillsdale Investment Management Inc. lifted its stake in shares of Bioventus by 148.7% in the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after purchasing an additional 401,230 shares during the period. Essex Investment Management Co. LLC acquired a new position in shares of Bioventus in the 4th quarter valued at $2,886,000. Kent Lake PR LLC acquired a new position in shares of Bioventus in the 2nd quarter valued at $2,317,000. Finally, Kennedy Capital Management LLC lifted its stake in shares of Bioventus by 219.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after purchasing an additional 317,157 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.